Disease · MONDO_0011972
ovarian hyperstimulation syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. ovarian hyperstimulation syndrome. Diseases, record MONDO_0011972. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011972
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs16
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CETRORELIX | CHEMBL1200490 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CORIFOLLITROPIN ALFA | CHEMBL2108185 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FOLLITROPIN BETA | CHEMBL5315126 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LETROZOLE | CHEMBL1444 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| POLYGELINE | CHEMBL2108135 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GONADORELIN | CHEMBL1007 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets |
| GONADORELIN ACETATE | CHEMBL1200511 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets |
| BROMOCRIPTINE | CHEMBL493 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DYDROGESTERONE | CHEMBL1200853 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUDROCORTISONE | CHEMBL1201388 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 16
See all 16 drugsTargets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | 5 | Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2798 | Drugs and targets |
| FSHR | Follicle-stimulating hormone receptor | 2 | Follicle stimulating hormone receptor agonist | Phase 3 | https://conductscience.org/library/genes/2492 | Drugs and targets |
| LHCGR | Lutropin-choriogonadotropic hormone receptor | 2 | Luteinizing hormone/Choriogonadotropin receptor agonist | Unknown | https://conductscience.org/library/genes/3973 | Drugs and targets |
| CYP19A1 | Aromatase | 1 | Cytochrome P450 19A1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1588 | Drugs and targets |
| CYSLTR1 | Cysteinyl leukotriene receptor 1 | 1 | Cysteinyl leukotriene receptor 1 antagonist | Phase 2 | https://conductscience.org/library/genes/10800 | Drugs and targets |
| DRD2 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Phase 2 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Phase 2 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| DRD4 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Phase 2 | https://conductscience.org/library/genes/1815 | Drugs and targets |
| PGR | Progesterone receptor | 1 | Progesterone receptor agonist | Phase 2 | https://conductscience.org/library/genes/5241 | Drugs and targets |
Trials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00702845 | To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001) | Phase 3 | 397 | 2015-04-27 | Infertility | CORIFOLLITROPIN ALFA, FOLLITROPIN BETA | Its record names the disease | ClinicalTrials.gov |
| NCT02823080 | Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome | Phase 2/3 | 48 | 2017-01-31 | Infertility | CETRORELIX | Its record names the disease | ClinicalTrials.gov |
| NCT03837223 | RESCUE PROTOCOL AND FRESH EMBRYO TRANSFER | 271 | GnRH Trigger and Rescue Protocol | GONADORELIN, GONADORELIN ACETATE | Its record names the disease | ClinicalTrials.gov | ||
| NCT05198128 | Ovarian Hyperstimulation Syndrome Using Calcium Infusion | Not applicable | 200 | Ovarian Hyperstimulation Syndrome | CALCIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT04351126 | Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response | Phase 2 | 107 | Ovarian Hyperstimulation Syndrome | BROMOCRIPTINE, FLUDROCORTISONE | Its record names the disease | ClinicalTrials.gov | |
| NCT01268761 | GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome | Phase 3 | 100 | Ovarian Hyperstimulation Syndrome, Effects of Gonadotropin, Oocyte Maturation | CETRORELIX | Its record names the disease | ClinicalTrials.gov | |
| NCT01973842 | Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients | Phase 2 | 90 | Subfertility | TRIPTORELIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02784457 | Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome | Phase 2 | 84 | Assisted Reproduction | CETRORELIX | Its record names the disease | ClinicalTrials.gov | |
| NCT02686151 | The Letrozole Administration During Luteal Phase | Phase 3 | 50 | Ovarian Hyperstimulation Syndrome | LETROZOLE, POLYGELINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02392520 | Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS) | Not applicable | 40 | Ovarian Hyperstimulation Syndrome | CETRORELIX, CETRORELIX ACETATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 100 μg Corifollitropin Alfa vs 150 IU recFSH: serious adverse events | 20 of 268 | 9 of 129 | 397 | NCT00702845 | Trial comparisons |
| Cetrotide vs no Cetrotide: deaths from any cause | 0 of 24 | 0 of 24 | 48 | NCT02823080 | Trial comparisons |
| Cetrotide vs no Cetrotide: serious adverse events | 0 of 24 | 0 of 24 | 48 | NCT02823080 | Trial comparisons |
Papers from its trials7
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011972
GET https://conductscience.org/api/diseases/v1/MONDO_0011972/drugs